secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001628280-25-051592
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar fails to align with FDA on zetomipzomib trial; cuts workforce 70%, begins strategic review
--------------------------------------------------------------------------------

- Unable to align with FDA on registrational trial for zetomipzomib in autoimmune hepatitis; strategic review with TD Cowen initiated.
- Workforce reduced by ~31 employees (70%); expects ~$6.0M in severance costs in Q4 2025.
- Repaid $6.3M to Oxford Finance in full; cash and marketable securities $90.2M at September 30, 2025.
- Net loss Q3 2025: $11.2M ($1.53/share) vs $20.3M ($2.78) in Q3 2024; R&D down to $6.9M from $16.2M.
- Retained essential employees for value creation; 7.3M shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000162828025051592/0001628280-25-051592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000162828025051592/kzr-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-051592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer